132 related articles for article (PubMed ID: 7512845)
21. Human bone marrow depleted of CD33-positive cells mediates delayed but durable reconstitution of hematopoiesis: clinical trial of MY9 monoclonal antibody-purged autografts for the treatment of acute myeloid leukemia.
Robertson MJ; Soiffer RJ; Freedman AS; Rabinowe SL; Anderson KC; Ervin TJ; Murray C; Dear K; Griffin JD; Nadler LM
Blood; 1992 May; 79(9):2229-36. PubMed ID: 1571539
[TBL] [Abstract][Full Text] [Related]
22. Preservation of lymphokine-activated killer activity following T cell depletion of human bone marrow.
Drobyski WR; Piaskowski V; Ash RC; Casper JT; Truitt RL
Transplantation; 1990 Oct; 50(4):625-32. PubMed ID: 1699309
[TBL] [Abstract][Full Text] [Related]
23. Bone marrow purging studies in acute myelogenous leukemia using the recombinant anti-CD33 immunotoxin HuM195/rGel.
Duzkale H; Pagliaro LC; Rosenblum MG; Varan A; Liu B; Reuben J; Wierda WG; Korbling M; McMannis JD; Glassman AB; Scheinberg DA; Freireich EJ
Biol Blood Marrow Transplant; 2003 Jun; 9(6):364-72. PubMed ID: 12813444
[TBL] [Abstract][Full Text] [Related]
24. Combination of interleukin-2-stimulated lymphocytes and bispecific antibodies that efficiently lyse leukemic cells does not affect bone marrow CD34-positive stem cell function in vitro.
Kaneko T; Fukuda J; Teramura M; Fusauchi Y; Kakui Y; Okumura K; Mizoguchi H; Oshimi K
Bone Marrow Transplant; 1994 Aug; 14(2):213-7. PubMed ID: 7527685
[TBL] [Abstract][Full Text] [Related]
25. Purging with 4-hydroperoxycyclophosphamide.
Jones RJ
J Hematother; 1992; 1(4):343-8. PubMed ID: 1345676
[TBL] [Abstract][Full Text] [Related]
26. Lymphokine-activated killer (LAK) cell purging of leukemic bone marrow: range of activity against different hematopoietic neoplasms.
Long GS; Cramer DV; Harnaha JB; Hiserodt JC
Bone Marrow Transplant; 1990 Sep; 6(3):169-77. PubMed ID: 2252956
[TBL] [Abstract][Full Text] [Related]
27. Pre-clinical evaluation of anti-lacto-N-fucopentaose III (CD15) monoclonal antibodies for ex vivo bone marrow purging in acute myeloid leukemia.
Guyotat D; Shi ZH; Campos L; Rabat M; Bonnier S; Poncelet P; Laurent JC; Fiere D
Bone Marrow Transplant; 1990 Dec; 6(6):385-90. PubMed ID: 1982926
[TBL] [Abstract][Full Text] [Related]
28. Effect of pharmacological purging on natural killer cell number and activity in human bone marrow.
Cardoso AA; Fallon M; Mukherji B; Silva MR; Marusic M; Gaffney J; Ascensao JL
Clin Immunol Immunopathol; 1992 Aug; 64(2):106-11. PubMed ID: 1643743
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of ex vivo purging for autologous bone marrow transplantation in the treatment of acute nonlymphoblastic leukemia.
Rowley SD; Jones RJ; Piantadosi S; Braine HG; Colvin OM; Davis J; Saral R; Sharkis S; Wingard J; Yeager AM
Blood; 1989 Jul; 74(1):501-6. PubMed ID: 2665843
[TBL] [Abstract][Full Text] [Related]
30. Lymphokine-activated killer (LAK) cell purging of bone marrow.
Cramer DV; Long GS
Prog Clin Biol Res; 1990; 333():125-35; discussion 136-7. PubMed ID: 2308977
[TBL] [Abstract][Full Text] [Related]
31. Adherent lymphokine-activated killer cells suppress autologous human normal bone marrow progenitors.
Miller JS; Verfaillie C; McGlave P
Blood; 1991 Jun; 77(11):2389-95. PubMed ID: 1903991
[TBL] [Abstract][Full Text] [Related]
32. The generation of human natural killer cells from CD34+/DR- primitive progenitors in long-term bone marrow culture.
Miller JS; Verfaillie C; McGlave P
Blood; 1992 Nov; 80(9):2182-7. PubMed ID: 1384796
[TBL] [Abstract][Full Text] [Related]
33. Ex vivo treatment of myeloma cells by 4-hydroperoxycyclophosphamide and VP-16-213.
Shimazaki C; Gulati SC; Atzpodien J; Fried J; Colvin OM; Clarkson BD
Acta Haematol; 1988; 80(1):17-22. PubMed ID: 3135688
[TBL] [Abstract][Full Text] [Related]
34. Prevention of graft-versus-host disease by selective depletion of CD6-positive T lymphocytes from donor bone marrow.
Soiffer RJ; Murray C; Mauch P; Anderson KC; Freedman AS; Rabinowe SN; Takvorian T; Robertson MJ; Spector N; Gonin R
J Clin Oncol; 1992 Jul; 10(7):1191-200. PubMed ID: 1607923
[TBL] [Abstract][Full Text] [Related]
35. Enhanced cytotoxic interaction between 5-fluorouracil and 4-hydroperoxycyclophosphamide against L1210 murine leukemic cells: applicability to ex vivo purging.
Mao XY; Higashigawa M; M'Soka T; Shimono Y; Nagata T; Inamochi H; Cao DC; Hori H; Kawasaki H; Sakurai M
Cancer Invest; 1999; 17(7):486-93. PubMed ID: 10518193
[TBL] [Abstract][Full Text] [Related]
36. In vitro effects of etoposide purging on natural killer cells.
Silva MR; Ascensao JL
J Hematother; 1995 Dec; 4(6):563-70. PubMed ID: 8846017
[TBL] [Abstract][Full Text] [Related]
37. Potential of phenylalanine methylester as a bone marrow purging agent.
Rosenfeld CS
Blood; 1992 Nov; 80(9):2401-5. PubMed ID: 1384802
[TBL] [Abstract][Full Text] [Related]
38. Enhanced lymphokine-activated killer cell activity by an immunomodulator, Roquinimex.
Vaz F; Silva MR; Ascensao JL
Br J Cancer; 1995 Dec; 72(6):1498-503. PubMed ID: 8519666
[TBL] [Abstract][Full Text] [Related]
39. In vitro sensitivity of human hematopoietic progenitor cells to 4-hydroperoxycyclophosphamide.
Ratajczak MZ; Ratajczak J; Kuczynski W; Light B; Lusk EJ; Gewirtz AM
Exp Hematol; 1993 Dec; 21(13):1663-7. PubMed ID: 8243568
[TBL] [Abstract][Full Text] [Related]
40. Improved outcome for high-risk acute myeloid leukemia patients using autologous bone marrow transplantation and monoclonal antibody-purged bone marrow.
Selvaggi KJ; Wilson JW; Mills LE; Cornwell GG; Hurd D; Dodge W; Gingrich R; Martin SE; McMillan R; Miller W
Blood; 1994 Mar; 83(6):1698-705. PubMed ID: 8123862
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
